Guardant Health (GH) said Wednesday that it is collaborating with German pharmaceutical company Boehringer Ingelheim to seek regulatory approval and commercialize Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer's investigational non-small cell lung cancer drug zongertinib.
Under the collaboration, Guardant said its Guardant360 CDx blood test would provide genomic profiling of tumors to help identify non-small cell lung cancer patients with HER2 mutations who may be eligible for treatment with zongertinib.
Guardant's shares were up 3% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments